Cantargia announce that the European Patent Office (EPO) has issued an Intention to grant notification for the company's divisional (second, follow-up) patent application regarding use of IL1RAP as a target for antibody therapy in solid tumors. The patent application has application number 15197139.7. Cantargia has previously received formal patent approval in Europe and other major territories for use of IL1RAP as target molecule for antibody therapy of several types of tumors.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Cantargia's lead project CAN04 (nidanilimab) is in clinical development, currently focused on treatment of non-small cell lung cancer and pancreatic cancer. Cantargia already holds an approved patent in Europe covering a method of using IL1RAP as target molecule for antibody treatment of solid tumors such as colon cancer, breast cancer and lung cancer. The patent provides protection until 2032. After grant of that patent, Cantargia submitted a follow-up patent application covering treatment of further solid tumor diseases and has now received an Intention to grant for this application from the EPO. If the application is formally approved Cantargia will have patent protection in the Europe for antibody based treatment against IL1RAP in the great majority of solid tumor types until 2032. Certain administrative steps remain before the final approval can be issued by EPO.
"We are very pleased that EPO intends to grant this patent application covering additional tumor forms. Strong patent protection in the field of IL1RAP antibodies and cancer therapy is of importance in our commercialization strategy. This preliminary approval is a further part in the robust protection that we are building globally," Göran Forsberg, CEO of Cantargia, said.